Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06LYI
|
|||
| Former ID |
DIB012098
|
|||
| Drug Name |
BPX-501
|
|||
| Indication | Acute lymphoblastic leukaemia [ICD-11: 2A85; ICD-10: C85.1, C88.7] | Phase 1/2 | [1] | |
| Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1/2 | [1] | ||
| Hematopoietic stem cell transplantation [ICD-11: QB63; ICD-10: Z00-Z99] | Phase 1/2 | [2] | ||
| Immunodeficiency [ICD-11: 4A00-4A85; ICD-9: 279.3] | Phase 1/2 | [3] | ||
| Osteoporosis [ICD-11: FB83.0; ICD-10: M85.8] | Phase 1/2 | [4] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1/2 | [1] | ||
| Company |
Bellicum pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | T-cells (T-cells) | Target Info | Immunomodulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | ClinicalTrials.gov (NCT01744223) Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.